Biopharmaceutical company Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) on Wednesday announced the acquisition of avexitide, a novel GLP-1 receptor antagonist, from Eiger BioPharmaceuticals Inc.
Avexitide has received FDA Breakthrough Therapy Designation for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI).
The GLP-1 receptor antagonist has shown significant efficacy in reducing severe hypoglycemic events in Phase 2 trials for PBH, achieving FDA-supported primary endpoints. Phase 3 trials for PBH are expected to commence in Q1 2025, with data anticipated in 2026. Avexitide demonstrated a favorable safety profile across five clinical trials.
Amylyx plans to integrate avexitide into its pipeline, which includes treatments for Wolfram syndrome, progressive supranuclear palsy and amyotrophic lateral sclerosis (ALS). The acquisition aligns with Amylyx's focus on addressing high unmet medical needs.
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD